Cancer treatments represented 33 per cent of medicines in all phases of clinical trials in 2023, followed by treatments for infectious diseases (13 per cent) and central nervous system diseases (12 per cent), according to a new report by the Patented Medicine Prices Review Board. It found more than 12,000 new medicines were undergoing clinical […]